Article Information
History
- July 1, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Hitoshi Kawasujia,
- Yasuhiro Tsujib,
- Keiko Miyakib,
- Takahiko Aoyamab,
- Fumihiro Kurosakib,
- Masayoshi Ezakia,
- Yuki Koshiyamaa,
- Yusuke Takegoshia,
- Makito Kanedaa,
- Yushi Muraia,
- Kou Kimotoa,
- Kentaro Nagaokaa and
- Yoshihiro Yamamotoa,*
- aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
- bLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, Funabashi, Chiba, Japan
- ↵*Corresponding author: Yoshihiro Yamamoto, MD, PhD Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences University of Toyama, 2630 Sugitani, Toyama 930-0194 Japan, Phone: +81-76-434-7245, Fax: +81-76-434-5018, E-mail: yamamoto{at}med.u-toyama.ac.jp
Posted July 01, 2024.
High feasibility of salivary therapeutic drug monitoring in linezolid, but less in tedizolid: A single-dose study in healthy subjects
